Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors

Inclusion Criteria

Inclusion criteria

1. Voluntary signed and dated written informed consent.

2. Patients with advanced solid tumors refractory to Standard therapy.

3. Age >/= 18 years.

4. Recovery from drug-related adverse events (AEs) of previous treatments, excluding
alopecia.

5. Normal laboratory values within seven days prior to treatment administration.

6. Women of childbearing potential must have a negative serum pregnancy test before
study entry. Both men and women must agree to use a medically acceptable method of
contraception throughout the treatment period and for three months after
discontinuation of treatment.

Exclusion criteria

1. Pregnant or lactating women.

2. Less than three weeks from radiation therapy or last dose of hormonal therapy,
biological therapy or chemotherapy

3. Prior treatment with any investigational product less than 30 days prior to the
first.

4. Central Nervous System metastases

5. Other relevant diseases or adverse clinical conditions:

- Increased cardiac risk:

- Presence of significant neurological or psychiatric disorders

- Neuropathy

- Active infection requiring treatment.

- Liver disease (e.g., cirrhosis, hepatitis).

- Immunocompromised patients.

- Any other major illness.

6. Limitation of the patient's ability to comply with the treatment.

7. Known hypersensitivity to any of the components of the drug product.